Analysts’ recommendations for Teva
Teva Pharmaceutical Industries (TEVA) reported its Q2 2018 earnings results yesterday and updated its fiscal 2018 guidance. In this article, we’ll look at analysts’ recommendations for Teva stock for the next 12 months. Of the 28 analysts covering Teva stock, 15 (~54%) recommend “hold,” six (~21%) recommend “buy” or “strong buy,” and seven (25%) recommend “sell.”
Target prices and revisions
Analysts’ consensus target price of $21.09 for Teva implies a 2.4% downside based on the stock’s closing price of $21.61 yesterday. Peers Eli Lilly (LLY), Pfizer (PFE), and Amgen (AMGN) have average broker target prices of $96.13, $40.3 and $204.3, respectively, which imply returns of -4.1%, 1.6%, and 4% over the next 12 months. After Teva reported its Q2 2018 results yesterday, Credit Suisse and Jefferies raised their target prices for TEVA stock from $23 to $25 and $19 to $21, respectively.
Check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!